Flucon150 mg

Flucon 150 mg is a broad-spectrum triazole antifungal agent indicated for the treatment and prevention of a wide range of fungal infections caused by susceptible Candida species, Cryptococcus neoformans, and dermatophytes. It is available in oral (capsule, tablet, suspension) and intravenous formulations, making it suitable for both superficial and life-threatening systemic fungal infections.

Candidal Infections

• Vaginal Candidiasis (Vulvovaginal Candidiasis) — the most common indication; a single oral dose effectively treats uncomplicated vaginal thrush caused by Candida albicans
• Oropharyngeal Candidiasis (Oral Thrush) — fungal infection of the mouth and throat, commonly seen in immunocompromised patients, denture wearers, and infants
• Esophageal Candidiasis — candidal infection of the esophagus, a significant opportunistic infection in HIV/AIDS and other immunocompromised states
• Invasive Candidal Infections — including candidemia (Candida in the bloodstream), peritonitis, and candidal infections of internal organs
• Disseminated Candidiasis — widespread candidal infection affecting multiple organs
• Superficial Candidiasis — cutaneous candidiasis affecting skin folds and mucosal surfaces
• Fungal Urinary Tract Infections — caused by susceptible Candida species

Cryptococcal Infections

• Cryptococcal Meningitis — a serious life-threatening infection of the meninges caused by Cryptococcus neoformans; Flucon 150 mg is used for both acute treatment and long-term maintenance/suppressive therapy (secondary prophylaxis) in HIV/AIDS patients
• Prevention of Cryptococcal Meningitis Relapse — long-term oral Flucon 150 mg is the standard of care for preventing relapse in patients who have been treated for cryptococcal meningitis
• Systemic Cryptococcal Infection — disseminated cryptococcal disease affecting the lungs, skin, or other organs

Dermatophyte and Superficial Fungal Infections

• Tinea Corporis — ringworm infection of the body (torso and limbs)
• Tinea Cruris — ringworm of the groin area (jock itch)
• Tinea Pedis — athlete's foot (fungal infection of the feet)
• Other Tinea Infections — including tinea capitis (scalp ringworm)
• Kerion — a severe inflammatory form of tinea capitis presenting as a boggy, painful scalp mass
• Pityriasis Versicolor (Tinea Versicolor) — a superficial fungal infection caused by Malassezia species, causing skin discoloration
• Onychomycosis — fungal nail infection (tinea unguium) affecting fingernails or toenails

Prophylaxis Indications

• Prevention of Fungal Infections in Immunocompromised Patients — including patients with HIV/AIDS, organ transplant recipients, and patients receiving immunosuppressive therapy
• Prophylaxis in Neutropenic Cancer Patients — prevention of invasive fungal infections during chemotherapy-induced neutropenia
• Prevention of Relapse of Cryptococcal Meningitis — long-term maintenance therapy in HIV/AIDS patients who have completed acute treatment

Other Systemic Fungal Infections

• Coccidioidomycosis — endemic dimorphic fungal infection
• Histoplasmosis — endemic mycosis; Flucon 150 mg used as alternative or step-down therapy

Triazole Antifungal Agents / Drugs for Subcutaneous and Systemic Mycoses

Flucon 150 mg is a member of the bis-triazole class of synthetic antifungal agents. It has a broad spectrum of antifungal activity against most clinically important pathogenic fungi and is distinguished by its excellent oral bioavailability, favorable pharmacokinetic profile, and good penetration into the central nervous system and other difficult-to-reach body compartments.

Mechanism of Action

Flucon 150 mg exerts its antifungal effect by selectively inhibiting fungal cytochrome P-450 14α-demethylase (also known as lanosterol 14α-demethylase, encoded by the CYP51 gene in fungi). This enzyme is an essential component of the fungal cytochrome P-450 enzyme system and is responsible for the conversion of lanosterol to ergosterol — the principal sterol in the fungal cell membrane, analogous to cholesterol in mammalian cell membranes.

By blocking this enzymatic step, Flucon 150 mg causes:

1. Depletion of ergosterol in the fungal cell membrane — ergosterol is essential for maintaining membrane fluidity, integrity, and function
2. Accumulation of toxic methylated sterol precursors (particularly 14α-methyllanosterol) that disrupt membrane structure and function
3. Increased membrane permeability — leading to leakage of intracellular contents and disruption of nutrient transport and enzyme function
4. Ultimately, inhibition of fungal cell growth and replication — Flucon 150 mg is primarily fungistatic at therapeutic concentrations, though it may be fungicidal against some organisms (notably Candida albicans and Cryptococcus neoformans) at higher concentrations

Selectivity: Flucon 150 mg has high selectivity for fungal over mammalian cytochrome P-450 enzymes (approximately 10,000-fold greater affinity for fungal CYP51), which accounts for its relatively favorable safety profile compared to older antifungals like amphotericin B. However, Flucon 150 mg does have some inhibitory activity on human liver CYP enzymes — particularly CYP2C9 and CYP3A4 — which is responsible for its clinically important drug-drug interactions.

Spectrum of Activity

• Highly active: Candida albicans, Candida tropicalis, Candida parapsilosis, Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, dermatophytes, Malassezia spp.
• Variable or reduced activity: Candida glabrata (now reclassified as Nakaseomyces glabrata) — may require higher doses; Candida krusei (now Pichia kudriavzevii) — intrinsically resistant to Flucon 150 mg
• Not active against: Aspergillus spp., Mucor spp., Fusarium spp., and other molds — Flucon 150 mg has no activity against filamentous fungi

Pharmacokinetics

• Absorption: Flucon 150 mg is almost completely absorbed following oral administration, with oral bioavailability exceeding 90% — the highest of any oral antifungal. Bioavailability is not significantly affected by food, gastric pH, or antacids, making it very convenient for clinical use.
• Peak plasma concentration (C_max): Reached within 1 to 2 hours after an oral dose.
• Distribution: Flucon 150 mg distributes widely into body tissues and fluids. It achieves excellent concentrations in skin, nails, vaginal tissue, saliva, sputum, urine, and — critically — cerebrospinal fluid (CSF). CSF concentrations are approximately 60–80% of plasma concentrations, making Flucon 150 mg uniquely effective for cryptococcal meningitis among oral antifungals. Plasma protein binding is low (approximately 11–12%), contributing to its high tissue penetration. Volume of distribution is approximately 0.6–0.8 L/kg.
• Metabolism: Flucon 150 mg undergoes minimal hepatic metabolism — only about 11% is converted to inactive metabolites. This is a key pharmacokinetic advantage compared to other azole antifungals (itraconazole, ketoconazole) which are extensively metabolized.
• Half-life: Approximately 30 hours in adults with normal renal function — the longest half-life among commonly used azoles. This long half-life enables once-daily dosing and makes single-dose therapy effective for vaginal candidiasis.
• Elimination: Approximately 80% of an oral dose is excreted unchanged in the urine, making it the antifungal of choice for fungal urinary tract infections. The remainder is excreted as metabolites. Renal impairment significantly reduces elimination and requires dose adjustment.

Oral Capsules and Tablets

• Flucon 150 mg capsules and tablets may be taken with or without food. Food does not significantly affect the absorption of Flucon 150 mg, giving flexibility in timing.
• Swallow capsules or tablets whole with a full glass of water.
• Flucon 150 mg may also be taken with milk, antacids, or following total body irradiation without any clinically significant impairment of absorption.
• For once-weekly dosing regimens (e.g., onychomycosis, tinea infections), try to take Flucon 150 mg on the same day each week to maintain a consistent schedule.
• For single-dose therapy (vaginal candidiasis, pityriasis versicolor), no special timing is required — take the dose at any convenient time.
• Complete the full course of treatment as directed by the physician, even if symptoms resolve early — premature discontinuation may lead to relapse or development of antifungal resistance.

Oral Suspension

• Flucon 150 mg oral suspension (50 mg/5 ml) is preferred for children and patients who cannot swallow capsules.
• Shake the bottle well before each use to ensure uniform distribution of the drug.
• Measure the dose using the calibrated measuring spoon or oral syringe provided — do not use a regular household teaspoon.
• The suspension may be taken with or without food.
• Store reconstituted suspension as directed on the label (typically in the refrigerator between 5°C–30°C); use within 14 days of reconstitution.

Intravenous (IV) Infusion

• Flucon 150 mg IV infusion (200 mg/100 ml, 2 mg/ml) is indicated for patients who cannot receive oral medication — typically in hospitalized patients with serious systemic fungal infections.
• Administer by intravenous infusion at a rate not exceeding 10 ml per minute (approximately 200 mg over 20–60 minutes). Do not administer as a rapid IV bolus injection.
• The IV formulation is compatible with Normal Saline (0.9% NaCl), 5% Dextrose in Water, Ringer's Lactate, and other standard IV fluids.
• Inspect the IV solution visually for particulate matter and discoloration before infusion. Discard if the solution appears cloudy or contains visible particles.
• Do not add other medications to the Flucon 150 mg infusion bag.
• The oral and IV dosages are identical — transition from IV to oral Flucon 150 mg should be made as soon as the patient can tolerate oral medication, since oral bioavailability approaches 90%.
• The IV solution should not be stored after opening; administer immediately and discard unused portions.

Flucon 150 mg is a significant inhibitor of hepatic cytochrome P-450 enzymes — particularly CYP2C9 and CYP3A4 — and to a lesser extent CYP2C19. This results in multiple clinically important drug interactions where Flucon 150 mg raises the plasma concentrations of co-administered drugs metabolized by these enzymes. The following interactions require careful management:

Warfarin and Coumarin Anticoagulants (Clinically Significant)

Flucon 150 mg inhibits CYP2C9, which is primarily responsible for the metabolism of the S-enantiomer of warfarin (the active form). Co-administration results in increased warfarin plasma levels and a measurable prolongation of prothrombin time (INR). Even a modest increase in INR (observed to be approximately 12% in controlled studies) can clinically increase bleeding risk. Close monitoring of INR/prothrombin time is mandatory when Flucon 150 mg is initiated, changed in dose, or discontinued in patients on warfarin. Warfarin dose reduction may be required.

Oral Sulfonylureas (Antidiabetic Drugs)

Flucon 150 mg prolongs the serum half-life of oral sulfonylurea antidiabetic agents including chlorpropamide, glibenclamide (glyburide), glipizide, and tolbutamide by inhibiting their CYP2C9-mediated metabolism. This can lead to significantly elevated plasma sulfonylurea levels and prolonged, potentially severe hypoglycemia. Flucon 150 mg and oral sulfonylureas may be co-administered in diabetic patients, but blood glucose must be carefully monitored and sulfonylurea dose reduction may be necessary.

Phenytoin (Anticonvulsant)

Concomitant administration of Flucon 150 mg and phenytoin may increase phenytoin plasma levels to a clinically significant degree, potentially causing phenytoin toxicity (nystagmus, ataxia, confusion, seizures). Regular monitoring of phenytoin plasma concentrations is essential when these drugs are co-administered. Phenytoin dose adjustment may be required.

Rifampicin (Rifampin)

Rifampicin is a potent inducer of CYP enzymes and significantly increases the metabolism of Flucon 150 mg. Co-administration of rifampicin results in approximately a 25% decrease in the AUC and a 20% shorter half-life of Flucon 150 mg — substantially reducing its antifungal efficacy. An increase in the Flucon 150 mg dose should be considered in patients receiving concurrent rifampicin therapy. Alternative antifungal agents may need to be considered in some settings.

Cyclosporin (Immunosuppressant)

Flucon 150 mg can increase cyclosporin plasma concentrations, primarily at higher doses (200 mg/day). The interaction is dose-dependent — 100 mg/day may not affect cyclosporin levels, while 200 mg/day has been shown to slowly increase them in renal transplant patients. Cyclosporin plasma concentration monitoring is recommended in all patients receiving both drugs, and cyclosporin dose adjustment may be required to avoid nephrotoxicity and other cyclosporin-related adverse effects.

Theophylline

Flucon 150 mg 200 mg administered for 14 days has been shown to reduce the mean plasma clearance of theophylline by approximately 18%, resulting in elevated theophylline plasma concentrations. Patients taking higher theophylline doses or those already at increased risk for theophylline toxicity (nausea, palpitations, seizures) should be monitored for signs of toxicity when Flucon 150 mg is added to therapy. Theophylline dose adjustment may be needed.

Hydrochlorothiazide (Diuretic)

Co-administration of multiple doses of hydrochlorothiazide with Flucon 150 mg increased Flucon 150 mg plasma concentrations by approximately 40%. While this magnitude of change does not normally necessitate a change in the Flucon 150 mg dose regimen, clinicians should be aware of potentially higher-than-expected Flucon 150 mg levels in patients on concurrent diuretic therapy.

Combined Oral Contraceptives

At standard doses (50 mg daily), Flucon 150 mg does not have a relevant effect on estrogen or progestogen levels in combined oral contraceptives. At 200 mg daily, the AUC of ethinyl estradiol was increased by approximately 40% and levonorgestrel by approximately 24%. At these higher doses, co-administration may theoretically increase the risk of estrogen-related side effects. At standard antifungal doses, no clinically significant impairment of contraceptive efficacy is expected.

QT-Prolonging Drugs

Flucon 150 mg inhibits CYP3A4 and can increase plasma levels of drugs that prolong the QTc interval, potentially increasing the risk of torsades de pointes. Exercise caution when co-administering Flucon 150 mg with drugs known to prolong the QT interval, including certain antihistamines (astemizole, terfenadine — contraindicated), antiarrhythmics, antipsychotics, and macrolide antibiotics.

No Clinically Significant Interactions With:

Interaction studies have shown no clinically significant pharmacokinetic interactions between oral Flucon 150 mg and the following: phenacetin, theophylline (at low doses), caffeine, propranolol, metoprolol, cyclosporin (100 mg/day), lidocaine, quinidine, estradiol, amoxicillin, antacids, cimetidine, food, alcohol, or following total body irradiation. No interactions have been demonstrated with piroxicam, diclofenac, or naproxen — making Flucon 150 mg compatible with NSAID therapy.

Flucon 150 mg is generally well tolerated, particularly at the lower doses used for superficial fungal infections. Most adverse effects are dose-dependent and occur more frequently at higher doses used for systemic infections. The following adverse effects have been reported:

Gastrointestinal Effects (Most Common — Approximately 5–10%)

• Nausea — the most frequently reported adverse effect
• Abdominal discomfort and cramping
• Diarrhea and loose stools
• Flatulence and bloating
• Dyspepsia and vomiting (less common)
• Altered or metallic taste (dysgeusia)

Skin and Hypersensitivity Reactions (Less than 1%)

• Skin rash — including urticarial and maculopapular eruptions; more common in patients with HIV/AIDS or other immunocompromised states
• Pruritus (itching)
• Serious cutaneous reactions (Rare):
  • Stevens-Johnson Syndrome (SJS) — a severe mucocutaneous reaction; patients must be monitored closely, particularly those with HIV/AIDS who are more prone to severe drug reactions
  • Toxic Epidermal Necrolysis (TEN) — a life-threatening severe cutaneous reaction
  • Exfoliative dermatitis and erythema multiforme
• Anaphylaxis — rare but has been reported; emergency management required

Important: If a rash develops in a patient being treated for a superficial fungal infection (e.g., tinea, vaginal candidiasis) that is attributable to Flucon 150 mg, the drug should be discontinued. In patients with invasive/systemic fungal infections who develop a rash, they should be monitored closely; Flucon 150 mg should be discontinued if bullous lesions or erythema multiforme develop.

Hepatic Effects (Uncommon to Rare)

• Elevated liver enzymes (ALT, AST, alkaline phosphatase, bilirubin) — may occur, particularly with prolonged therapy or in patients with pre-existing liver disease
• Hepatitis — rare, usually reversible
• Cholestatic jaundice — rarely reported
• Hepatic necrosis (Very Rare) — extremely rare, observed primarily in severely ill patients with multiple comorbidities and concurrent potentially hepatotoxic medications; a causal relationship with Flucon 150 mg cannot be excluded in all cases. Liver enzyme levels should be monitored during prolonged therapy.

Neurological Effects

• Headache (uncommon, approximately 2%)
• Dizziness and lightheadedness
• Seizures — rare; most commonly in patients with underlying neurological conditions

Hematological Effects (Rare)

• Leukopenia (reduced white blood cell count)
• Thrombocytopenia (reduced platelet count)
• These are typically reversible upon discontinuation and may be related to underlying disease rather than Flucon 150 mg itself, particularly in patients with AIDS or cancer

Other Effects

• QTc interval prolongation — more relevant at higher doses or in combination with other QT-prolonging drugs
• Hypokalemia — reported rarely, particularly at high doses
• Adrenal insufficiency — prolonged high-dose Flucon 150 mg may theoretically reduce adrenal steroid synthesis, but no clinically significant effect on endogenous steroid levels has been documented at standard doses

Pregnancy

Flucon 150 mg should not be used during pregnancy and should not be used in women of childbearing potential unless adequate contraception is employed. Here is the evidence basis:

• Animal studies: Adverse fetal effects (embryotoxicity and teratogenicity including skeletal malformations) have been observed in animal studies, but only at dose levels many times in excess of those recommended for human therapeutic use and which were also associated with maternal toxicity.
• Human data: There has been limited clinical use during human pregnancy. Post-marketing surveillance reports have identified a pattern of rare but serious birth defects (including cardiac defects and cleft palate — a phenotype referred to as "Flucon 150 mg embryopathy") in a small number of infants born to mothers who received prolonged, high-dose Flucon 150 mg (400–800 mg/day) during pregnancy, particularly during the first trimester.
• Single low-dose exception: Some regulatory agencies and clinical guidelines note that a single oral dose of 150 mg for vaginal candidiasis may be the lowest-risk option if treatment during pregnancy is unavoidable. However, the prescribing physician must weigh the risks and benefits carefully and consider topical azole therapy as the preferred alternative in pregnancy.
• Women of childbearing potential who require multi-dose or prolonged Flucon 150 mg therapy must use reliable contraception during treatment and for a period after completion.

Lactation

Flucon 150 mg is found in human breast milk at concentrations similar to plasma concentrations. Because of this substantial transfer into breast milk and the potential for adverse effects on the nursing infant (including exposure of the infant to therapeutic drug levels), Flucon 150 mg is not recommended during breastfeeding. If Flucon 150 mg treatment is considered essential for the mother, breastfeeding should be discontinued during therapy.

Driving and Use of Machinery

Experience with Flucon 150 mg indicates that therapy is unlikely to impair a patient's ability to drive or operate machinery. Occasional dizziness has been reported; patients should assess their individual response before driving.

Hepatotoxicity Monitoring

In some patients — particularly those with serious underlying diseases such as AIDS or cancer — abnormalities in hepatic function tests have been observed during Flucon 150 mg treatment. In very rare cases, severe hepatic reactions including hepatic necrosis have been reported, primarily in severely ill patients receiving multiple concomitant potentially hepatotoxic medications or with underlying conditions that could independently cause liver damage. The risk-benefit ratio of continued Flucon 150 mg treatment should be reassessed in any patient in whom a significant rise in liver enzymes occurs. Flucon 150 mg should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to Flucon 150 mg.

Severe Cutaneous Reactions

Patients have rarely developed serious exfoliative cutaneous reactions — including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) — during Flucon 150 mg treatment. Patients with HIV/AIDS are more prone to the development of severe cutaneous reactions to many drugs, including Flucon 150 mg. The following rules apply:

• If a rash develops in a patient being treated for a superficial fungal infection that is considered attributable to Flucon 150 mg, further therapy with this agent should be discontinued.
• In patients with invasive or systemic fungal infections who develop rashes, they should be monitored closely and Flucon 150 mg should be discontinued if bullous lesions or erythema multiforme develop.

QT Interval Prolongation

Cases of QT prolongation and torsades de pointes have been reported during post-marketing surveillance in patients receiving Flucon 150 mg, predominantly in patients with serious underlying conditions or co-medications that may contribute to QTc prolongation. Use with extreme caution — or avoid — in patients with:

• Pre-existing QT prolongation
• Electrolyte disturbances (hypokalemia, hypomagnesemia)
• Concurrent use of other QT-prolonging drugs
• Clinically significant bradyarrhythmia

Renal Impairment — Dose Adjustment

Since Flucon 150 mg is predominantly excreted unchanged in the urine, dose adjustment is required in patients with significant renal impairment receiving multiple-dose therapy. Normal loading doses should be administered on Days 1 and 2, followed by adjusted dosing intervals or doses based on creatinine clearance (see Dosage section). Failure to adjust the dose in renally impaired patients may lead to drug accumulation and toxicity.

Drug Interactions — Vigilance Required

Flucon 150 mg is a potent inhibitor of CYP2C9 and CYP3A4 enzymes. Review all concurrent medications before initiating Flucon 150 mg, particularly anticoagulants, antiepileptics, immunosuppressants, antidiabetics, and QT-prolonging drugs. Many drug-drug interactions may be clinically significant even at low Flucon 150 mg doses.

Antifungal Resistance

Flucon 150 mg resistance has been increasingly reported, particularly in non-albicans Candida species. Candida krusei is intrinsically resistant, and Candida glabrata often shows dose-dependent susceptibility or frank resistance. Culture and susceptibility testing is recommended for treatment failures, recurrent infections, or invasive infections to guide appropriate therapy.

Use in Immunocompromised Patients

Extra vigilance is required in patients with AIDS, organ transplantation, or malignancy. These patients are more susceptible to both severe fungal infections and adverse drug reactions (particularly hepatic and cutaneous). More frequent monitoring of liver function tests, renal function, and complete blood counts is advisable.

There is no specific antidote for Flucon 150 mg overdose. Reported cases of Flucon 150 mg overdose have described hallucinations and paranoid behavior as potential symptoms. In general, Flucon 150 mg overdose management follows these principles:

• Symptomatic and supportive care is the mainstay of treatment
• Gastric lavage may be considered if the overdose was taken recently (within 1 hour) and the patient can protect their airway
• Forced diuresis (increasing urine volume with IV fluids) would probably increase the elimination rate of Flucon 150 mg, given that it is predominantly excreted unchanged in the urine
• Hemodialysis can significantly reduce Flucon 150 mg plasma levels — a 3-hour hemodialysis session has been shown to decrease plasma levels by approximately 50%. This may be considered in severe overdose cases, particularly in patients with renal impairment
• Monitor liver and renal function, cardiac rhythm (for QT prolongation), and electrolytes

In the event of suspected Flucon 150 mg overdose, contact a poison control center or seek emergency medical care immediately.

• Store capsules, tablets, and dry powder for suspension below 25°C–30°C, in a cool, dry place away from direct light, heat, and moisture.
• Keep all formulations out of the reach of children.
• Do not use any formulation after the expiry date printed on the label or packaging.
• Oral suspension (after reconstitution): Store between 5°C and 30°C. Do not freeze. Most reconstituted suspensions should be used within 14 days of preparation — check the specific product label for the exact storage period. Shake well before each use.
• IV infusion solution: Store below 25°C in the original packaging, protected from light. Do not freeze. Once opened, administer immediately and discard any unused portion — do not store opened IV bottles for later use.
• Store all Flucon 150 mg products in their original packaging to protect from light and moisture exposure.

Elderly Patients

The normal adult dose should be used in elderly patients who show no evidence of renal impairment. Since renal function frequently declines with age, renal function (creatinine clearance) should be assessed before initiating and during multiple-dose Flucon 150 mg therapy. Dose adjustment per the renal impairment guidelines should be applied in elderly patients with creatinine clearance below 40 mL/min. Elderly patients are also at higher risk for drug-drug interactions due to polypharmacy.

Pediatric Patients (Children Over 1 Year)

Flucon 150 mg is approved for use in children over 1 year of age at weight-based doses. Renal clearance in children may be proportionately more rapid than in adults. Doses up to 12 mg/kg/day may be used in serious life-threatening infections in children aged 5–13 years (maximum 400 mg/day). The oral suspension formulation is preferred for young children. The safety of Flucon 150 mg in neonates (under 1 year) has not been fully established, though it is used in this age group in specialist settings under close clinical supervision.

Patients with Renal Impairment

Since Flucon 150 mg is excreted predominantly in the urine as unchanged drug, renal impairment significantly affects drug accumulation and elimination. No adjustment is needed for single-dose therapy. For multiple-dose therapy, normal loading doses should be administered on Days 1 and 2, followed by dose adjustment based on creatinine clearance (see Dosage section). In patients on regular hemodialysis, one full dose should be given after each dialysis session since a 3-hour hemodialysis session removes approximately 50% of plasma Flucon 150 mg. Peritoneal dialysis removes Flucon 150 mg less efficiently.

Patients with Hepatic Impairment

Flucon 150 mg undergoes minimal hepatic metabolism and is primarily renally eliminated. However, caution should be exercised in patients with severe hepatic impairment. Liver function tests should be monitored during Flucon 150 mg therapy in patients with pre-existing hepatic disease. If significant liver enzyme elevations occur during treatment, the risk-benefit ratio of continued therapy must be reassessed. Flucon 150 mg should be discontinued if clinical liver disease attributable to the drug develops.

Immunocompromised Patients (HIV/AIDS, Transplant, Cancer)

Immunocompromised patients frequently require higher doses, longer treatment durations, and long-term suppressive (maintenance) therapy. They are at greater risk of both invasive fungal infections requiring aggressive treatment and serious adverse drug reactions. Careful monitoring of hepatic, renal, and hematological parameters is essential during prolonged therapy. Culture and susceptibility testing is particularly important in this population to detect antifungal resistance.